Ju Hee Bang
New Generation University College
30 Papers
19 Citations
Ju Hee Bang is an academic researcher from New Generation University College. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 8, co-authored 17 publications.
Chat about Author
Papers
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Do Youn Oh,Kyung Eun Lee,Dae Won Lee,Jeesun Yoon,Tae-Yong Kiim Kim,Ju Hee Bang,Ah Rong Nam,Kyoung Seok Oh,Jae-Min Kim,Young S. Lee,Violeta Beleva Guthrie,Patricia McCoon,Weimin Li,Song Wu,Qu Zhang,Marlon Rebelatto,Jin Won Kim +16 more
TL;DR: Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with advanced biliary tract cancer as mentioned in this paper , and patients were not masked to the treatment group.
245
Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
TL;DR: Bosutinib showed more potent antitumor effects in Src-activated HR cell lines than parental cell lines, and Src inhibition may be an effective measure to overcome trastuzumab resistance in HER2-positive cancer.
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
Hyun-Kyung Park,Ju Hee Bang,Ah Rong Nam,Ji Eun Park,Mei Hua Jin,Yung Jue Bang,Yung Jue Bang,Do Youn Oh,Do Youn Oh +8 more
TL;DR: The sPD-L1 level at diagnosis exhibits a prognostic value in pancreatic cancer and could be used to understand various changes in the tumor microenvironment during chemotherapy.
Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.
Jin Won Kim,Kyung Hun Lee,Kyung Hun Lee,Ji Won Kim,Koung Jin Suh,Ah Rong Nam,Ju Hee Bang,Yung-Jue Bang,Yung-Jue Bang,Do Youn Oh,Do Youn Oh +10 more
TL;DR: A combination of binimetinib and capecitabine shows acceptable tolerability and promising antitumor efficacy for gem citabine-pretreated BTC, especially in patients with RAS/RAF/MEK/ERK pathway mutations.
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers
Mei Hua Jin,Ah Rong Nam,Ju Hee Bang,Kyoung Seok Oh,Hye Rim Seo,Hye Rim Seo,Jae Min Kim,Jae Min Kim,Jeesun Yoon,Tae Yong Kim,Tae Yong Kim,Do Youn Oh,Do Youn Oh,Do Youn Oh +13 more
TL;DR: Wang et al. as mentioned in this paper found higher PD-L1 expression in trastuzumab-resistant (HR) HER2-positive cancer cells than in parental cells, and blocking PD-l1 reversed the resistance to trastrazumab in HR cells.
20